Acquired factor XIII inhibitor: Clinical features, treatment, fibrin structure and epitope determination

Haemophilia

Volumn 17, Issue 3, 2011, Pages 393-398

  Luo, Y Y ^a   Zhang, G S ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Epitope; Factor XIII; Fibrin structure; Inhibitor; Treatment

Indexed keywords

AMINOCAPROIC ACID; AMIODARONE; BATROXOBIN; BLOOD CLOTTING INHIBITOR; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; EPITOPE; FIBRIN; FRESH FROZEN PLASMA; HEMOGLOBIN; ISONIAZID; METHYLPREDNISOLONE; PENICILLIN G; PHENYTOIN; PRACTOLOL; PREDNISONE;

ACQUIRED BLOOD CLOTTING FACTOR 13 INHIBITION; ADULT; AUTOIMMUNE DISEASE; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD CLOTTING TEST; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE ASSOCIATION; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LABORATORY DIAGNOSIS; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTOR INHIBITORS; EPITOPES; FACTOR VIII; FACTOR XIII DEFICIENCY; FEMALE; FIBRIN; HEMORRHAGE; HEMORRHAGIC DISORDERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 79955126230     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02459.x     Document Type: Review

References (49)

1. Shen L, Lorand L. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. J Clin Invest 1983; 71: 1336-41.
2. Gladner JA, Nossal R. Effects of crosslinking on the rigidity and proteolytic susceptibility of human fibrin clots. Thromb Res 1983; 30: 273-88.
3. Hornyak T, Bishop PD, Shafer JA. α-Thrombin-catalyzed activation of human platelet factor XIII: relationship between proteolysis and factor XIII activity. Biochemistry 1989; 28: 7326-32.
4. Lorand L, Gray AJ, Brown K et al. Dissociation of the subunit structure of fibrin stabilizing factor during activation of the zymogen. Biochem Biophys Res Commun 1974; 56: 914-22.
5. Curtis CG, Brown KL, Credo RB et al. Calcium-dependent unmasking of active center cysteine during activation of fibrin stabilizing factor. Biochemistry 1974; 13: 3774-80.
6. Lorand L, Urayama T, Atencio AC, Hsia DY. Inheritance of deficiency of fibrin-stabilizing factor (factor 13). Am J Hum Genet 1970; 22: 89-95.
7. Mikkola H, Yee VC, Syrjala M et al. Four novel mutations in deficiency of coagulation factor XIII: consequences to expression and structure of the A-subunit. Blood 1996; 87: 141-51.
8. Louhichi N, Medhaffar M, Hadjsalem I et al. Congenital factor XIII deficiency caused by two mutations in eight Tunisian families: molecular confirmation of a founder effect. Ann Hematol 2010; 89: 499-504.
9. Krumdieck R, Shaw DR, Huang ST, Poon MC, Rustagi PK. Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenstrom's macroglobulinemia. Am J Med 1991; 90: 639-45.
10. Lopaciuk S, Bykowska K, McDonagh JM et al. Difference between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder. J Clin Invest 1978; 61: 1196-203.
11. McDevitt NB, McDonagh J, Taylor HL, Roberts HR. An acquired inhibitor to factor XIII. Arch Intern Med 1972; 130: 772-7.
12. Lim W, Moffat K, Hayward CP. Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency. J Thromb Haemost 2004; 2: 1017-9.
13. Weinberg JB, Pippen AM, Greenberg CS. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1991; 34: 996-1005.
14. Milner GR, Holt PJ, Bottomley J, Maciver JE. Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII. J Clin Pathol 1977; 30: 770-3.
15. Ahmad F, Solymoss S, Poon MC, Berube C, Sullivan AK. Characterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus. Br J Haematol 1996; 93: 700-3.
16. Lorand L, Velasco PT, Hill JM, Hoffmeister KJ, Kaye FJ. Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against actor XIII. Thromb Haemost 2002; 88: 919-23.
17. Okubo S, Yamano M, Yasunaga K. A case with SLE showing acquired low plasma FXIII level followed by severe hematoma characteristic of FXIII deficiency. Rinsho Ketsueki. 1988; 29: 1522-6.
18. Ajzner E, Schlammadinger A, Kerenyi A et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood 2009; 113: 723-5.
19. Luo Y, Zhang G, Zuo W, Zheng W, Dai C. Acquired factor XIII inhibitor in monoclonal gammopathy of undetermined significance: characterization and cross-linked fibrin ultrastructure. Ann Hematol 2010; 89: 833-4.
20. Lorand L, Velasco PT, Rinne JR, Amare M, Miller LK, Zucker ML. Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (factor XIII) system. Proc Natl Acad Sci U S A 1988; 85: 232-6.
21. Lorand L, Velasco PT, Murthy SN, Lefebvre P, Green D. Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner. Blood 1999; 93: 909-17.
22. Gregory TF, Cooper B. Case report of an acquired factor XIII inhibitor: diagnosis and management. Proc (Bayl Univ Med Cent) 2006; 19: 221-3.
23. Lorand L. Hemorrhagic disorders of fibrin stabilization. In Ogston D, Bennett B eds. Hemostasis: Biochemistry, Physiology and Pathology. London: John Wiley & Sons Ltd, 1977: 405-23.
24. Lewis JH, Szeto IL, Ellis LD, Bayer WL. An acquired inhibitor to coagulation factor 13. Johns Hopkins Med J 1967; 120: 401-7.
25. Lorand L, Maldonado N, Fradera J et al. Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII). Br J Haematol 1972; 23: 17-27.
26. Otis PT, Feinstein DI, Rapaport SI, Patch MJ. An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations. Blood 1974; 44: 771-81.
27. Rosenberg RD, Colman RW, Lorand L. A new haemorrhagic disorder with defective fibrin stabilization and cryofibrinogenaemia. Br J Haematol 1974; 26: 269-84.
28. Ragaz S, Kemp G, Furlan M, Beck EA. Bleeding disorder with abnormal wound healing, acid-soluble clots and normal factor XIII. Thromb Haemost 1976; 36: 537-41.
29. Godal HC, Ly B. An inhibitor of activated factor XIII, inhibiting fibrin cross-linking but not incorporation of amine into casein. Scand J Haematol 1977; 19: 443-8.
30. Shires L, Gomperts ED, Bradlow BA. An acquired inhibitor to factor XIII. A case report. S Afr Med J 1979; 56: 70-2.
31. Fear JD, Miloszewski KJ, Losowsky MS. An acquired inhibitor of factor XIII with a qualitative abnormality of fibrin cross-linking. Acta Haematol 1984; 71: 304-9.
32. Nakamura S, Kato A, Sakata Y, Aoki N. Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide. Br J Haematol 1988; 68: 313-9.
33. Daly HM, Carson PJ, Smith JK. Intracerebral haemorrhage due to acqured factor XIII inhibitor -successful response to factor XIII concentrate. Blood Coagul Fibrinolysis 1991; 2: 507-14.
34. Gailani D. An IgG inhibitor against coagulation factor XIII: resolution of bleeding after plasma immunoadsorption with staphylococcal protein A. Am J Med 1992; 92: 110-2.
35. Fukue H, Anderson K, McPhedran P, Clyne L, McDonagh J. A unique factor XIII inhibitor to a fibrin-binding site on factor XIIIA. Blood 1992; 79: 65-74.
36. Seiving B, Henriksson P, Stenberg P, Nilsson IM. A reversed activity staining procedure for detection of an acquired antibody against factor XIII in a girl with factor XIII deficiency. Br J Haematol 1992; 82: 414-6.
37. Manco-Johnson M, Nuss R, Lefkowitz J, Nugent D. Characterization and quantitation of an inhibitor to the A chain of Factor XIII (F XIII) in a child with severe factor XIII deficiency [abstract]. Blood 1993; 82: 596a.
38. Donnet A, Trefouret S, Alessi MC et al. [Intradural hematoma of the foramen magnum associated with factor XIII deficiency]. Rev Neurol (Paris) 1994; 150: 164-6.
39. Tosetto A, Rodeghiero F, Gatto E, Manotti C, Poli T. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. Am J Hematol 1995; 48: 34-9.
40. Nakazawa M, Iida R, Tanoue K, Arai M. Successful gastrectomy in a patient with inhibitor activities to factor XIII and phospholipid-mediated clotting time [abstract]. Thromb Haemost 1997; 35: PS- 137.
41. Huth-Kühne A, Lages P, Zimmermann R. Intracranial hemorrhage in a patient with congenital factor XIII deficiency and inhibitor - successful treatment with Ig-immunoadsorption and high dose continuous factor XIII infusion [abstract]. Blood 1998; 92: 106b.
42. Fardella P, Conte G, Gonzalez N, Cuneo M. An acquired inhibitor to factor XIII (case report) [abstract]. Blood 1999; 94: 95b.
43. Xiarchopoulou P, Andreopoulost A, Kotsi P, Kouramba A. A case of an acquired inhibitor of factor XIII. J Thromb Haemost, 2003; 1: P0297.
44. Nijenhuis AV, Van Bergeijk L, Huijgens PC, Zweegman S. Acquired factor XIII deficiency due to an inhibitor: a case report and review of the literature. Haematologica 2004; 89: ECR14.
45. Miesbach W, Boehm M, Scharrer I. Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin. Thromb Haemost 2005; 93: 1001-3.
46. Heriksson P, McDonagh J, Villa M. Type I autoimmune inhibitor of factor XIII in a patient with congenital factor XIII deficiency. Thromb Haemost 1983; 50: 272.
47. Lorand L, Urayama T, De Kiewiet J, Nossel HL. Diognositic and genetic studies on fibrin stabilising factor with a new assay based on amine incorporation. J Clin Invest 1969; 48: 1054-64.
48. Standeven KF, Carter AM, Grant PJ et al. Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood 2007; 110: 902-7.
49. Jάmbor C, Reul V, Schnider TW, Degiacomi P, Metzner H, Korte WC. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood. Anesth Analg 2009; 109: 1023-8.